Imiquimod (Aldara) Cream has not been evaluated for the treatment of urethral, intravaginal, cervical, rectal or intra-anal human papilloma viral disease and is not recommended for these conditions. The diagnosis of sBCC should be confirmed prior to treatment since safety and effectiveness of Imiquimod (Aldara) Cream have not been established for other types of basal cell carcinomas including nodular, morpheaform (fibrosing or sclerosing) types and is not recommended for treatment of BCC subtypes other than the superficial variant (ie, sBCC). Patients with sBCC treated with Imiquimod (Aldara) Cream are recommended to have regular follow-up of treatment site. See Table 4 in Pharmacology: Pharmacokinetics: Clinical studies under Actions.
Sign Out
